Skip to main
DXCM

DexCom (DXCM) Stock Forecast & Price Target

DexCom (DXCM) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 48%
Buy 38%
Hold 10%
Sell 5%
Strong Sell 0%

Bulls say

DexCom is positioned for significant growth driven by key momentum factors, including anticipated Medicare expansion and additional coverage wins that are expected to increase the number of covered lives significantly. The company's focus on innovation, particularly with the G7 15-day continuous glucose monitoring system and improvements in adhesive technology enhancing sensor survival, supports a favorable outlook for revenue growth in the mid-teens and over 20% in earnings per share through 2028. Furthermore, operational efficiency gains and an expanding sales force are expected to contribute to sustained profitability, bolstering DexCom's overall financial performance.

Bears say

The financial analysis reveals a negative outlook on DexCom's stock due to several key factors: first, while sensor revenue has increased to $1.18 billion, the significant decline of 31% in hardware revenue signals potential weaknesses in product demand and diversification. Additionally, the company's forecast for Q1 2026 indicates a sequential revenue decline of 6-7%, suggesting ongoing challenges in maintaining consistent growth, especially as the sales mix shifts toward pharmacy distribution. Lastly, the fiscal year 2026 revenue guidance falls short of consensus expectations and indicates further deceleration in sales, which may lead to downward revisions in estimates, placing additional pressure on the stock.

DexCom (DXCM) has been analyzed by 21 analysts, with a consensus rating of Buy. 48% of analysts recommend a Strong Buy, 38% recommend Buy, 10% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DexCom (DXCM) Forecast

Analysts have given DexCom (DXCM) a Buy based on their latest research and market trends.

According to 21 analysts, DexCom (DXCM) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $85.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $85.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DexCom (DXCM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.